I have a 60-year-old male patient and since three to four years, he is having a problem of acute breathlessness and cough. Uh, he had unilateral pleural effusion on right side and on auscultating today also, there are creps on right side and he has dry cough. Uh, he had undergone multiple CT scans in the past, which only show consolidations. And also, the pleural fluid ADA is normal. The pleural fluid is hemorrhagic. Um, it's red in color. Um, bronchoscopy. "The respiratory medicine person gave diagnosis of query sarcoidosis, but he has not yet confirmed sarcoidosis. RA factor is raised, it's around 226, and the CCP is normal." Uh, "There is on and off fever. There is no history of cont- or contact with a, with tuberculosis. And at last, he was started with ATD." How can I manage this patient further since the tuberculosis is not yet confirmed? Is there any possibility of interstitial lung disease in this patient?
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
pleural effusion AND diagnosis
Searching the Web
British Thoracic Society unilateral pleural effusion guideline diagnostic workup 2023
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading Article
PMID: 42270119
Reading Web Page
https://www.brit-thoracic.org.uk/document-library/guidelines…
This is an undiagnosed chronic unilateral hemorrhagic pleural effusion with persistent right-sided parenchymal abnormality, not yet a confirmed diagnosis of tuberculosis, sarcoidosis, rheumatoid lung disease, or ILD. He needs prompt reassessment by an experienced respiratory/pleural service, ideally with rheumatology input.
If he currently has significant acute breathlessness, hypoxemia, chest pain, confusion, high fever, or hemodynamic instability, refer him to the emergency department now.
Key interpretation
- Normal pleural-fluid ADA makes TB pleuritis less likely, particularly in a low-TB-prevalence setting, but it does not entirely exclude it. It should not be the sole decision point.
- A hemorrhagic unilateral effusion should make you actively exclude malignancy, pulmonary embolism/infarction, pleural infection, trauma/iatrogenic bleeding, and less commonly autoimmune pleuritis.
- Sarcoid pleural effusion is uncommon, generally occurring with more obvious pulmonary and/or extrapulmonary sarcoidosis. It requires compatible imaging plus tissue showing non-caseating granulomas, after excluding TB and fungi.
- Raised serum rheumatoid factor alone does not diagnose rheumatoid arthritis or rheumatoid pleuritis. A negative anti-CCP does not rule out RA, but the clinical history of inflammatory arthritis, morning stiffness, joint swelling, nodules, sicca symptoms, rashes, etc. is essential.
- ILD is possible, including connective-tissue-disease-associated ILD or RA-associated ILD, but ILD by itself does not usually explain a recurrent hemorrhagic unilateral pleural effusion. The pleural disease needs its own diagnostic pathway.
Immediate priorities
1. Review all prior imaging, not only the reports
Ask a thoracic radiologist to compare all CTs and obtain a current contrast-enhanced CT chest, if not already done, focused on:
- Pleural thickening, nodularity, diaphragmatic/mediastinal pleural involvement
- Lung mass, endobronchial lesion, lymphadenopathy
- Rounded atelectasis versus persistent consolidation
- Features of organizing pneumonia, fibrosis, UIP/NSIP pattern, bronchiectasis, or aspiration
- Pulmonary embolism or infarction, if clinically plausible
A dedicated HRCT ILD protocol is appropriate only after the fluid/pleura and current consolidation are evaluated. It should include thin inspiratory images, and prone/expiratory images when indicated.
2. Re-sample the pleural fluid properly, under ultrasound guidance
If fluid persists or recurs, send a fresh, adequately sized sample for:
- Paired serum and pleural protein and LDH to classify by Light criteria
- Cell count and differential
- Pleural fluid pH, glucose, LDH
- Gram stain and aerobic/anaerobic bacterial culture
- AFB smear and mycobacterial culture
- Mycobacterial NAAT/Xpert where locally validated, recognizing that fluid tests can have limited sensitivity
- Fungal testing where epidemiologically relevant
- Cytology with cell block, ideally 25 to 50 mL for suspected malignancy
- Consider flow cytometry if lymphoma is a concern
- Pleural-fluid hematocrit, with simultaneous peripheral blood hematocrit. Fluid hematocrit >50% of blood hematocrit suggests hemothorax, rather than simply a blood-stained effusion.
- Pleural fluid RF, glucose, pH and complement if rheumatoid pleuritis remains a serious possibility
The 2023 BTS pleural guideline advises image-guided aspiration, cytology as an initial test for suspected malignancy, and pleural tissue culture as the preferred diagnostic sample when TB pleuritis is suspected.
3. Obtain pleural tissue if this remains unexplained
With chronic unilateral hemorrhagic exudative effusion, recurrent symptoms, and nondiagnostic CT/bronchoscopy/fluid studies, the next high-yield step is usually:
- Image-guided pleural biopsy if focal pleural thickening/nodules are seen, or
- Medical thoracoscopy/pleuroscopy with multiple pleural biopsies, plus samples for histology, mycobacterial/fungal cultures and molecular testing.
This is more important than repeating nonspecific blood markers. The BTS guideline supports thoracoscopic or image-guided biopsy in undiagnosed unilateral effusion. A recent systematic review found high diagnostic yields for medical thoracoscopy and image-guided pleural biopsy, while blind closed biopsy performed worse (2026 systematic review, PMID 42270119).
Specific diagnoses to prioritize
| Diagnosis | Why it remains possible | What would help establish or exclude it |
|---|---|---|
| Pleural/lung malignancy, including mesothelioma or metastatic cancer | Age 60, chronic unilateral hemorrhagic effusion, persistent consolidation | Contrast CT review, cytology with cell block, pleural biopsy/thoracoscopy |
| Tuberculous pleuritis | Fever and local epidemiology may support it | Pleural tissue histology plus mycobacterial culture/NAAT. ADA is supportive only, not definitive |
| Pulmonary embolism with infarction | Can cause unilateral bloody effusion and peripheral consolidation | Clinical probability assessment, CT pulmonary angiography when appropriate, leg ultrasound |
| Rheumatoid pleuritis or RA-associated lung disease | Male sex, high RF, possible pleural and parenchymal disease | Careful joint/systemic examination, rheumatology review, pleural glucose/pH/LDH/RF, HRCT and PFTs |
| Sarcoidosis | Previously suggested, but not confirmed | Typical HRCT pattern, extrapulmonary findings, biopsy-proven non-caseating granulomas after microbiologic exclusion |
| Chronic infection or non-TB infection | Fever, consolidation, chronic cough | Sputum/BAL cultures and targeted tests, but biopsy may still be needed |
| Organizing pneumonia or other inflammatory parenchymal disease | “Consolidation” may represent an inflammatory pattern | HRCT review and sometimes transbronchial/cryobiopsy or surgical biopsy, depending on pattern and safety |
Is RA-associated ILD possible?
Yes, but call it a possibility, not a diagnosis. RA-associated lung disease can include ILD, bronchiectasis, bronchiolitis, nodules, pleural thickening, and effusion. However:
- He needs evidence that he truly has RA or another connective-tissue disease.
- A high RF may occur in other autoimmune disease, chronic infection, some malignancies, and with age.
- Anti-CCP negativity reduces specificity for RA but does not exclude it.
- The HRCT must be reviewed specifically for ILD patterns. RA-ILD often shows a UIP-like pattern with basal/subpleural reticulation, traction bronchiectasis and possibly honeycombing, not merely “consolidation.”
- Perform spirometry, lung volumes, DLCO, resting and exertional oxygen saturation, and echocardiography if pulmonary hypertension or cardiac disease is possible.
What to do about the current anti-tuberculous therapy
Do not label the patient as TB solely on the basis of fever, consolidation, or an empiric treatment trial. The decision to continue, pause, or alter anti-TB drugs must be made by the treating respiratory physician or infectious-disease/TB specialist after reviewing:
- TB prevalence and pre-test probability
- Exact ADA value and fluid differential
- All cultures, NAAT/Xpert tests, sputum/BAL results and prior biopsy reports
- Whether adequate pleural tissue samples can be collected promptly
- Clinical stability and response to treatment
- Drug toxicity monitoring
If he is stable and there is no microbiologic or histologic confirmation, it is reasonable to seek definitive pleural sampling urgently rather than allowing empiric therapy to delay a diagnosis of cancer, PE, or autoimmune pleural disease. In a high-burden setting, empiric therapy may sometimes be justified, but it should be documented as a probability-based decision and reviewed against objective clinical and radiologic response.
Practical referral plan
Arrange, urgently:
- Respiratory physician with pleural-procedure expertise.
- Thoracic radiology review of all scans.
- Ultrasound-guided diagnostic thoracentesis, if fluid remains.
- Image-guided pleural biopsy or medical thoracoscopy if fluid testing is nondiagnostic.
- Rheumatology assessment, including examination for inflammatory arthritis and focused autoimmune work-up.
- Pulmonary function tests with DLCO and HRCT ILD protocol once the immediate pleural diagnosis is being addressed.
- Baseline CBC, ESR/CRP, renal/liver function, albumin, coagulation profile, HIV testing where appropriate, and echocardiography/NT-proBNP if cardiac contribution is plausible.
The central issue is: exclude pleural malignancy and obtain pleural tissue for TB culture/histology before accepting sarcoidosis, RA pleuritis, or ILD as the explanation.
Can inositol help in concieving pregnancy
Reading File
Finding Sources
Searching PubMed
inositol AND polycystic ovary syndrome AND fertility
Searching the Web
2023 international evidence based guideline polycystic ovary syndrome inositol fertility recommendation
Inositol may help some people with PCOS, particularly if irregular ovulation is related to insulin resistance. It may improve menstrual regularity and ovulation in some cases. However, it is not proven to reliably increase clinical pregnancy or live-birth rates, so it should not be relied upon as a fertility treatment.
The 2023 international PCOS guideline considers inositol for infertility experimental, because evidence for ovulation, pregnancy, and live birth remains limited and uncertain (PCOS guideline recommendation). A 2024 systematic review informing that guideline reached a similar conclusion (systematic review, PMID 38163998).
Practical advice
- If you have PCOS and irregular periods, discuss myo-inositol with your gynecologist. It can be a reasonable optional supplement, but not a substitute for proven ovulation-induction treatment.
- If trying to conceive, take folic acid 400-800 micrograms daily unless your clinician advises a higher dose.
- Track ovulation and have intercourse every 1-2 days in the fertile window.
- For PCOS-related infertility, letrozole is generally the first-line medication for ovulation induction, prescribed and monitored by a clinician.
- Supplements vary in dose and quality. Avoid products with many unverified additives, and tell your doctor about all supplements.
Seek a fertility assessment after 12 months of trying if under 35, 6 months if age 35 or older, or sooner if periods are very irregular/absent, there is known PCOS, prior pelvic infection/endometriosis, or a male-factor concern.
This is a shared conversation. Sign in to Orris to start your own chat.